PiracetamvsTianeptine

Piracetam modulates AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and NMDA (N-methyl-D-aspartate) glutamate receptors through positive allosteric modulation, enhancing excitatory neurotransmission without direct agonism. It increases membrane fluidity of neuronal phospholipid bilayers by reducing membrane microviscosity, which improves ion channel function and signal transmission. Piracetam enhances acetylcholine receptor density and turnover in the hippocampus, upregulating both muscarinic (M1) and nicotinic receptor expression. It potentiates the cholinergic system through increased high-affinity choline uptake. Additionally, piracetam improves cerebral blood flow via nitric oxide-dependent vasodilation and enhances oxygen utilization (glucose metabolism) in aged or hypoxic brain tissue, supporting mitochondrial function.

Tianeptine is a full agonist at mu-opioid (MOR) and delta-opioid (DOR) receptors, mediating both its antidepressant/anxiolytic effects and abuse potential at high doses. Paradoxically, it enhances serotonin reuptake via SERT—opposite to SSRIs—yet still produces antidepressant effects, possibly through opioid-mediated mood regulation. Tianeptine modulates glutamatergic signaling by reversing stress-induced downregulation of AMPA receptor subunits (GluA1/GluA2) and restoring synaptic plasticity. In the hippocampus and amygdala, it prevents stress-induced dendritic atrophy, spine loss, and CA3 pyramidal cell damage—likely through opioid receptor activation and downstream HPA axis effects. It increases BDNF levels and promotes neurogenesis. The combination of opioid agonism, glutamate normalization, and neuroplasticity enhancement underlies its unique profile.